Zura Bio Limited (ZURA)
ZURAPrice: $5.95
Fair Value: 🔒
🔒score
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutrali... more
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for ... more
Description
Shares
| Market Cap | $386.88M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Sandeep C. Kulkarni |
| IPO Date | 2023-03-21 | CAGR | — |
| Employees | 30 | Website | zurabio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ZURA chart loading...
Fundamentals
Technicals
| Enterprise Value | $411.30M | P/E Ratio | -5.61 |
| Forward P/E | -59.5 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 6.75 |
| P/CF Ratio | -10.56 | P/FCF Ratio | -7.28 |
| EPS | $-1.06 | EPS Growth 1Y | 94.67% |
| EPS Growth 3Y | -642.86% | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.84% | ROA | -0.87% |
| ROCE | -0.74% | Current Ratio | 9.05 |
| Quick Ratio | 9.05 | Cash Ratio | 8.82 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | 14.99 | Piotroski Score | 1 |